Articles dans des revues avec comité de lecture (396)
  1. 373. Awada, A., Di Leo, A., & Piccart-Gebhart, M. (2000). New Biological approaches to the treatment of cancer with a focus on breast cancer. Bulletin du cancer, 87(1), 49-62.
  2. 374. Piccart-Gebhart, M., & Awada, A. (2000). State-of-the-art chemotherapy for advanced breast cancer. Seminars in oncology, 27(5 SUPPL. 9), 3-12.
  3. 375. Awada, A., Leo, A., & Piccart-Gebhart, M. (2000). Actualités thérapeutiques dans le cancer du sein. Bulletin du cancer, 87(1), 49-62.
  4. 376. Awada, A., Punt, C., Piccart-Gebhart, M., Van Tellingen, O., Van Manen, L., Kerger, J., Groot, Y., Wanders, J., Verweij, J., & Wagener, T. (1999). Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule. British Journal of Cancer, 79(9-10), 1454-1461. doi:10.1038/sj.bjc.6690232
  5. 377. Awada, A. (1999). Cytoprotection of Amifostine from radiochemotherapy and radioiodine therapy in head and neck cancer patients: strong signs of efficacy but not yet a standard treatment. Opinions on topics in supportive care, 30, 5.
  6. 378. Hamilton, A., Awada, A., & Piccart-Gebhart, M. (1998). Agents other than taxanes in active development for the treatment of breast cancer. Current medical literature. Breast cancer, 10(2), 35-50.
  7. 379. Van Tellingen, O., Punt, C., Awada, A., Wagener, T., Piccart-Gebhart, M., Groot, Y., Schaaf, L. J., Henrar, R. E., Nooijen, W. J., & Beijnen, J. H. (1998). A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study. Cancer chemotherapy and pharmacology, 41(5), 377-384.
  8. 380. Burris, H. A., Raymond, E., Awada, A., Kuhn, J., O'Rourke, T. J., Brentzel, J., Lynch, W., King, S., Brown, T. D., & Von Hoff, D. D. (1998). Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies. Investigational new drugs, 16(1), 19-27.
  9. 381. Klastersky, J., & Awada, A. (1997). La gemcitabine : Un nouvel agent pour la chimiothérapie des cancers solides. Revue médicale de Bruxelles, 18(5), 328-334.
  10. 382. de Valeriola, D., Awada, A., Roy, J. A., Di Leo, A., Biganzoli, L., & Piccart-Gebhart, M. (1997). Breast cancer therapies in development. A review of their pharmacology and clinical potential. Drugs, 54(3), 385-413.
  11. 383. Kusenda, Z., Kerger, J., Awada, A., Geurs, F., Van Vreckem, A., Habboubi, N., & Piccart-Gebhart, M. (1997). Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC). Supportive care in cancer, 5(5), 414-416. doi:10.1007/s005200050101
  12. 384. Piccart-Gebhart, M., Klijn, J. G., Paridaens, R., Nooij, M., Mauriac, L., Coleman, R., Bontenbal, M., Awada, A., Selleslags, J., Van Vreckem, A., & van Glabbeke, M. (1997). Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. Journal of clinical oncology, 15(9), 3149-3155.
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>